ATHIRA PHARMA INC (ATHA)
US04746L1044 - Common Stock
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing...
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected...
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
On Wednesday, Athira Pharma, Inc. (NASDAQ:ATHA) stock is trading lower after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer’s disease (AD). A -0.08 change in GST (the Global Statistical Test, a combination of results from measures of cognition (ADAS-Cog11) and function (ADCS-ADL23) favoring fosgonimeton that did not reach statistical significance (p=0.70) The change in cognition from baseline, for which a decrease fro
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23) In pre-specified...
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024
ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the second quarter of 2024.
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Athira Pharma (NASDAQ:ATHA) just reported results for the second quarter of 202...
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates ...
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau...
Tuesday Sector Leaders: Manufacturing, Drugs
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Wednesday 6/26 Insider Buying Report: PX, ATHA
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients...
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
First-in-human, dose escalation study to evaluate safety, tolerability and pharmacokinetics in healthy volunteers with trial completion expected by year-end 2024
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)...
Athira Pharma to Participate in Upcoming June Conferences
Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second Half of 2024
Athira Pharma to Participate in Upcoming June Conferences
Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second...
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...
ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Athira Pharma (NASDAQ:ATHA) just reported results for the first quarter of 2024...
ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024
ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the first quarter of 2024.
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates...